PIA
PTCT icon

Piedmont Investment Advisors’s PTC Therapeutics PTCT Stock Holding History

Piedmont Investment Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-786
Closed -$27K – 1967
2018
Q2 		$27K Buy
+786
New +$24.5K ﹤0.01% 1493

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Piedmont Investment Advisors's PTCT Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 786 shares — an estimated $27K sold.

Piedmont Investment Advisors first reported a position in PTCT in Q2 2018 and held it in 1 quarter. The position peaked at $27K in Q2 2018. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 786 PTC Therapeutics shares in Q3 2018, an estimated $27K.
  • Piedmont Investment Advisors first reported a position in PTC Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's PTC Therapeutics position peaked at $27K in Q2 2018.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.